Status:

TERMINATED

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Lead Sponsor:

Diamyd Therapeutics AB

Conditions:

Type 1 Diabetes Mellitus

Eligibility:

All Genders

10-20 years

Phase:

PHASE3

Brief Summary

The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with...

Eligibility Criteria

Inclusion

  • Main
  • Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening
  • Fasting C-peptide level at time of screening above 0.1 nmol/L
  • Elevated GAD65 antibodies (GADA) at time of screening
  • Male and female patients between 10 and 20 years of age
  • Main

Exclusion

  • Treatment with immunosuppressants or any anti-diabetic medications other than insulin
  • A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)
  • Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine
  • Participation in other clinical trials with a new chemical entity within the previous 3 months
  • Pregnancy or planned pregnancy within 1 year after the last Diamyd dose
  • Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2012

Estimated Enrollment :

331 Patients enrolled

Trial Details

Trial ID

NCT00751842

Start Date

September 1 2008

End Date

July 1 2012

Last Update

October 10 2012

Active Locations (43)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (43 locations)

1

University of Arizona

Tucson, Arizona, United States, 85724

2

Arkansas Children's Hospital Research Institute

Little Rock, Arkansas, United States, 72202

3

Alex Endocrine Associates

Rogers, Arkansas, United States, 72758

4

Children's Hospital Orange County

Orange, California, United States, 92868

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT | DecenTrialz